Mailian Medical Secures $14.9M Series B for BCI Therapy

Mailian Medical has raised $14.9 million in a Series B round to advance its brain-computer interface therapy program, according to Dealroom's deal tracker.

The financing is the strongest signal yet of investor confidence in the company's therapeutic approach. Brain-computer interfaces (systems that record neural signals, typically via scalp EEG or intracranial electrodes, and translate them into device commands or therapeutic output) have drawn growing venture interest as clinical applications broaden beyond assistive communication.

What the round confirms

The $14.9 million Series B provides Mailian Medical with capital to push its interface-based therapy toward later development stages. The deal was logged by Dealroom, which tracks financing events across the medical technology sector.

The source reporting on the round does not specify:

• the identity of the lead investor or the syndicate;
• the valuation at which the round closed;
• a precise timeline for regulatory submission or clinical trials.

Readers tracking the BCI therapeutic field should therefore treat the financing amount as the confirmed fact, with platform details pending company disclosure.

How this fits the therapeutic BCI segment

Mailian Medical enters a segment in which several companies are testing interface-based interventions for neurological and psychiatric indications. Such programs generally rely on chronic neural recording — intracranial electrode arrays or non-invasive scalp EEG — combined with decoding software that drives stimulation or neurofeedback protocols.

The company has not yet stated which recording modality its therapy platform uses, nor whether any component has received regulatory clearance. Until Mailian Medical publishes those specifications, the distinction between investigational work and a cleared device remains open.

For clinical neurophysiology teams, the practical relevance lies in what follows: therapeutic BCIs that reach trials will need electrophysiology laboratories capable of high-quality long-duration recordings, quantified signal metrics, and rigorous artifact control — capabilities that monitoring units and reading rooms already possess.

What comes next

Series B capital of this size typically funds pivotal-scale engineering and early clinical validation. Whether Mailian Medical moves toward a first-in-human study, expands an existing trial cohort, or pursues regulatory clearance will clarify the platform's maturity. The company's next disclosures on modality, indication, and trial design will determine how quickly its therapy moves from financing headline to clinical protocol.